2026 H1 - tulosraportti
68 päivää sitten
‧45 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 13 381 | ||
| 13 381 | ||
| 26 761 | ||
| 1 | ||
| 844 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H2 - tulosraportti 26.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 H1 - tulosraportti 28.8. | ||
2025 H2 - tulosraportti 26.2. | ||
2025 H1 - tulosraportti 29.8.2025 | ||
2024 H2 - tulosraportti 26.2.2025 | ||
2024 H1 - tulosraportti 30.8.2024 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·5 min sittenWhere do you think this stock is in say 3-5 years. Have just started saving a bit in stocks. Have everything in Thor and will buy as I have money to spare. It is not large sums like some talk about in here, but still what I manage to set aside with 4 kids, a normally good job and income But thinking about whether it is better to put my money in a fund or something. Is just more exciting to follow Thor and what they manage to achieve going forward, but what is really the point if Max rise is small change against a fund..- ·9 t sittenI think this one will go up a bit now, awaiting news about the US venture. So when that arrives it could be fun 👍 dvs this is wishful thinking from me 🤣🙈
Now that the Democrats have regained the majority in both chambers, we can expect the threat of major budget cuts against the research environment to disappear. It is highly likely that the new majority will roll back Trump's attempt to freeze research funds, thus once again ensuring strong public budgets for the cancer research that Thor Medical's American customers live on 
·14 t sittenOut of pure curiosity, how many shares do people hold and what is the average price? I just got in myself, have 118 000 at an average of 4.05.
~173,000. Got approx 4.4-4.5 due to different platforms. Plans to sit until the market is well mature unless major fundamental changes happen to the market/company.- ·15 t sittenFrom facebook group: After the merger of Thor Medical AS and Nordic Nanovector ASA in 2024, all the patents of the old Nanovector ended up in a separate company called Nuclithera AS. Thor Medical AS has a sharing agreement where they get a % share of a future profit if Nuclithera succeeds. This without requirement for new equity regardless of future share issues in Nuclithera AS. Quite unique, and in addition to the tax losses carried forward of approx 3 billion that Thor Medical AS took over, this is a future asset very few are aware of. Now Nuclithera has succeeded with funding for an extensive CD37 development pathway based on the old patent. ................................................ NucliThera Awarded NOK 16 Million in Research Council Funding to Advance Next-Generation CD37-Targeted Cancer Therapy October 29, 2026 NucliThera AS is pleased to announce that the Research Council of Norway (Forskningsrådet) has approved funding for its Next-Generation CD37 project under the Innovation Project for the Industrial Sector (IPN) programme. The four-year project, with approximately NOK 16 million in public funding, will support the development of a new generation of targeted radionuclide therapies for hematological cancers. The project focuses on developing novel radioconjugates targeting CD37, a protein expressed on several types of blood cancer cells. By combining humanized antibody-based targeting molecules with lead-212 (²¹²Pb), an alpha-emitting radionuclide, NucliThera aims to develop highly targeted therapies capable of delivering potent radiation directly to malignant cells while limiting exposure to healthy tissues. Building on NucliThera’s established CD37 antibody platform and previous research, the project will focus on optimizing therapeutic candidates, improving their biological distribution and stability, and evaluating their safety and efficacy in preclinical models. The project will be conducted in collaboration with Oslo University Hospital, combining NucliThera’s expertise in radiopharmaceutical development with established capabilities in preclinical cancer research. Its objective is to identify and characterize a lead therapeutic candidate and generate the preclinical evidence and manufacturing documentation needed to support future clinical development. "This funding represents an important milestone for NucliThera and a strong recognition of the scientific and therapeutic potential of our CD37 platform. It allows us to accelerate the development of next-generation radiopharmaceuticals while strengthening our collaboration with leading Norwegian research institutions," said Roy Larsen, Chairman of the Board and Chief Technology Officer of NucliThera. The award further strengthens NucliThera’s research and development portfolio and supports the company’s long-term strategy of advancing innovative targeted radionuclide therapies toward clinical application. About NucliThera AS: NucliThera is an R&D company developing targeted radionuclide therapies for cancer, including lymphoma and leukaemia. Its research combines therapeutic radionuclides with monoclonal antibodies or small molecules to deliver radiation to cancer cells while limiting damage to surrounding healthy tissue. NucliThera’s research team is jointly led by Chief Scientific Officer Dr Ada RepettoLlamazares, Chief Technology Officer Dr Roy H. Larsen and Chief Medical Officer Professor Emeritus Øyvind S. Bruland. Dr Larsen and Professor Bruland’s pioneering work includes the development of Xofigo, an alpha-emitting therapy for bone metastases from prostate cancer.Check stock exchange announcement regarding this from 2024/2025. Thor Medical has signed an agreement with Nuclithera where Nuclithera has taken over all patents free of charge in exchange for a revenue-sharing agreement that is confidential. It is only this agreement that is relevant for former Nannolitters. It still requires ownership in Thor Medical
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 H1 - tulosraportti
68 päivää sitten
‧45 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·5 min sittenWhere do you think this stock is in say 3-5 years. Have just started saving a bit in stocks. Have everything in Thor and will buy as I have money to spare. It is not large sums like some talk about in here, but still what I manage to set aside with 4 kids, a normally good job and income But thinking about whether it is better to put my money in a fund or something. Is just more exciting to follow Thor and what they manage to achieve going forward, but what is really the point if Max rise is small change against a fund..
- ·9 t sittenI think this one will go up a bit now, awaiting news about the US venture. So when that arrives it could be fun 👍 dvs this is wishful thinking from me 🤣🙈Now that the Democrats have regained the majority in both chambers, we can expect the threat of major budget cuts against the research environment to disappear. It is highly likely that the new majority will roll back Trump's attempt to freeze research funds, thus once again ensuring strong public budgets for the cancer research that Thor Medical's American customers live on
- ·14 t sittenOut of pure curiosity, how many shares do people hold and what is the average price? I just got in myself, have 118 000 at an average of 4.05.~173,000. Got approx 4.4-4.5 due to different platforms. Plans to sit until the market is well mature unless major fundamental changes happen to the market/company.
- ·15 t sittenFrom facebook group: After the merger of Thor Medical AS and Nordic Nanovector ASA in 2024, all the patents of the old Nanovector ended up in a separate company called Nuclithera AS. Thor Medical AS has a sharing agreement where they get a % share of a future profit if Nuclithera succeeds. This without requirement for new equity regardless of future share issues in Nuclithera AS. Quite unique, and in addition to the tax losses carried forward of approx 3 billion that Thor Medical AS took over, this is a future asset very few are aware of. Now Nuclithera has succeeded with funding for an extensive CD37 development pathway based on the old patent. ................................................ NucliThera Awarded NOK 16 Million in Research Council Funding to Advance Next-Generation CD37-Targeted Cancer Therapy October 29, 2026 NucliThera AS is pleased to announce that the Research Council of Norway (Forskningsrådet) has approved funding for its Next-Generation CD37 project under the Innovation Project for the Industrial Sector (IPN) programme. The four-year project, with approximately NOK 16 million in public funding, will support the development of a new generation of targeted radionuclide therapies for hematological cancers. The project focuses on developing novel radioconjugates targeting CD37, a protein expressed on several types of blood cancer cells. By combining humanized antibody-based targeting molecules with lead-212 (²¹²Pb), an alpha-emitting radionuclide, NucliThera aims to develop highly targeted therapies capable of delivering potent radiation directly to malignant cells while limiting exposure to healthy tissues. Building on NucliThera’s established CD37 antibody platform and previous research, the project will focus on optimizing therapeutic candidates, improving their biological distribution and stability, and evaluating their safety and efficacy in preclinical models. The project will be conducted in collaboration with Oslo University Hospital, combining NucliThera’s expertise in radiopharmaceutical development with established capabilities in preclinical cancer research. Its objective is to identify and characterize a lead therapeutic candidate and generate the preclinical evidence and manufacturing documentation needed to support future clinical development. "This funding represents an important milestone for NucliThera and a strong recognition of the scientific and therapeutic potential of our CD37 platform. It allows us to accelerate the development of next-generation radiopharmaceuticals while strengthening our collaboration with leading Norwegian research institutions," said Roy Larsen, Chairman of the Board and Chief Technology Officer of NucliThera. The award further strengthens NucliThera’s research and development portfolio and supports the company’s long-term strategy of advancing innovative targeted radionuclide therapies toward clinical application. About NucliThera AS: NucliThera is an R&D company developing targeted radionuclide therapies for cancer, including lymphoma and leukaemia. Its research combines therapeutic radionuclides with monoclonal antibodies or small molecules to deliver radiation to cancer cells while limiting damage to surrounding healthy tissue. NucliThera’s research team is jointly led by Chief Scientific Officer Dr Ada RepettoLlamazares, Chief Technology Officer Dr Roy H. Larsen and Chief Medical Officer Professor Emeritus Øyvind S. Bruland. Dr Larsen and Professor Bruland’s pioneering work includes the development of Xofigo, an alpha-emitting therapy for bone metastases from prostate cancer.Check stock exchange announcement regarding this from 2024/2025. Thor Medical has signed an agreement with Nuclithera where Nuclithera has taken over all patents free of charge in exchange for a revenue-sharing agreement that is confidential. It is only this agreement that is relevant for former Nannolitters. It still requires ownership in Thor Medical
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 13 381 | ||
| 13 381 | ||
| 26 761 | ||
| 1 | ||
| 844 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H2 - tulosraportti 26.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 H1 - tulosraportti 28.8. | ||
2025 H2 - tulosraportti 26.2. | ||
2025 H1 - tulosraportti 29.8.2025 | ||
2024 H2 - tulosraportti 26.2.2025 | ||
2024 H1 - tulosraportti 30.8.2024 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 H1 - tulosraportti
68 päivää sitten
‧45 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H2 - tulosraportti 26.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 H1 - tulosraportti 28.8. | ||
2025 H2 - tulosraportti 26.2. | ||
2025 H1 - tulosraportti 29.8.2025 | ||
2024 H2 - tulosraportti 26.2.2025 | ||
2024 H1 - tulosraportti 30.8.2024 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·5 min sittenWhere do you think this stock is in say 3-5 years. Have just started saving a bit in stocks. Have everything in Thor and will buy as I have money to spare. It is not large sums like some talk about in here, but still what I manage to set aside with 4 kids, a normally good job and income But thinking about whether it is better to put my money in a fund or something. Is just more exciting to follow Thor and what they manage to achieve going forward, but what is really the point if Max rise is small change against a fund..
- ·9 t sittenI think this one will go up a bit now, awaiting news about the US venture. So when that arrives it could be fun 👍 dvs this is wishful thinking from me 🤣🙈Now that the Democrats have regained the majority in both chambers, we can expect the threat of major budget cuts against the research environment to disappear. It is highly likely that the new majority will roll back Trump's attempt to freeze research funds, thus once again ensuring strong public budgets for the cancer research that Thor Medical's American customers live on
- ·14 t sittenOut of pure curiosity, how many shares do people hold and what is the average price? I just got in myself, have 118 000 at an average of 4.05.~173,000. Got approx 4.4-4.5 due to different platforms. Plans to sit until the market is well mature unless major fundamental changes happen to the market/company.
- ·15 t sittenFrom facebook group: After the merger of Thor Medical AS and Nordic Nanovector ASA in 2024, all the patents of the old Nanovector ended up in a separate company called Nuclithera AS. Thor Medical AS has a sharing agreement where they get a % share of a future profit if Nuclithera succeeds. This without requirement for new equity regardless of future share issues in Nuclithera AS. Quite unique, and in addition to the tax losses carried forward of approx 3 billion that Thor Medical AS took over, this is a future asset very few are aware of. Now Nuclithera has succeeded with funding for an extensive CD37 development pathway based on the old patent. ................................................ NucliThera Awarded NOK 16 Million in Research Council Funding to Advance Next-Generation CD37-Targeted Cancer Therapy October 29, 2026 NucliThera AS is pleased to announce that the Research Council of Norway (Forskningsrådet) has approved funding for its Next-Generation CD37 project under the Innovation Project for the Industrial Sector (IPN) programme. The four-year project, with approximately NOK 16 million in public funding, will support the development of a new generation of targeted radionuclide therapies for hematological cancers. The project focuses on developing novel radioconjugates targeting CD37, a protein expressed on several types of blood cancer cells. By combining humanized antibody-based targeting molecules with lead-212 (²¹²Pb), an alpha-emitting radionuclide, NucliThera aims to develop highly targeted therapies capable of delivering potent radiation directly to malignant cells while limiting exposure to healthy tissues. Building on NucliThera’s established CD37 antibody platform and previous research, the project will focus on optimizing therapeutic candidates, improving their biological distribution and stability, and evaluating their safety and efficacy in preclinical models. The project will be conducted in collaboration with Oslo University Hospital, combining NucliThera’s expertise in radiopharmaceutical development with established capabilities in preclinical cancer research. Its objective is to identify and characterize a lead therapeutic candidate and generate the preclinical evidence and manufacturing documentation needed to support future clinical development. "This funding represents an important milestone for NucliThera and a strong recognition of the scientific and therapeutic potential of our CD37 platform. It allows us to accelerate the development of next-generation radiopharmaceuticals while strengthening our collaboration with leading Norwegian research institutions," said Roy Larsen, Chairman of the Board and Chief Technology Officer of NucliThera. The award further strengthens NucliThera’s research and development portfolio and supports the company’s long-term strategy of advancing innovative targeted radionuclide therapies toward clinical application. About NucliThera AS: NucliThera is an R&D company developing targeted radionuclide therapies for cancer, including lymphoma and leukaemia. Its research combines therapeutic radionuclides with monoclonal antibodies or small molecules to deliver radiation to cancer cells while limiting damage to surrounding healthy tissue. NucliThera’s research team is jointly led by Chief Scientific Officer Dr Ada RepettoLlamazares, Chief Technology Officer Dr Roy H. Larsen and Chief Medical Officer Professor Emeritus Øyvind S. Bruland. Dr Larsen and Professor Bruland’s pioneering work includes the development of Xofigo, an alpha-emitting therapy for bone metastases from prostate cancer.Check stock exchange announcement regarding this from 2024/2025. Thor Medical has signed an agreement with Nuclithera where Nuclithera has taken over all patents free of charge in exchange for a revenue-sharing agreement that is confidential. It is only this agreement that is relevant for former Nannolitters. It still requires ownership in Thor Medical
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 13 381 | ||
| 13 381 | ||
| 26 761 | ||
| 1 | ||
| 844 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt